Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
38.90
0.00 (0.00%)
Dec 31, 2025, 4:00 PM EST - Market closed
Castle Biosciences Revenue
Castle Biosciences had revenue of $83.04M in the quarter ending September 30, 2025, a decrease of -3.19%. This brings the company's revenue in the last twelve months to $343.53M, up 10.15% year-over-year. In the year 2024, Castle Biosciences had annual revenue of $332.07M with 51.09% growth.
Revenue (ttm)
$343.53M
Revenue Growth
+10.15%
P/S Ratio
3.25
Revenue / Employee
$451,419
Employees
761
Market Cap
1.14B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 332.07M | 112.28M | 51.09% |
| Dec 31, 2023 | 219.79M | 82.75M | 60.38% |
| Dec 31, 2022 | 137.04M | 42.95M | 45.65% |
| Dec 31, 2021 | 94.09M | 31.44M | 50.18% |
| Dec 31, 2020 | 62.65M | 10.78M | 20.79% |
| Dec 31, 2019 | 51.87M | 29.08M | 127.62% |
| Dec 31, 2018 | 22.79M | 9.03M | 65.67% |
| Dec 31, 2017 | 13.75M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CSTL News
- 14 days ago - Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 16 days ago - Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma - GlobeNewsWire
- 21 days ago - Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer - GlobeNewsWire
- 24 days ago - Expert Melanoma Panel Recommends Castle Biosciences' DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma - GlobeNewsWire
- 6 weeks ago - Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year - GlobeNewsWire
- 7 weeks ago - New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity - GlobeNewsWire
- 7 weeks ago - Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 2 months ago - Why Castle Biosciences' Rally Might Just Be Getting Started - Benzinga